Have you seen any increased dermatologic toxicity with whole breast or chest wall radiation if patients have received recent or concurrent pembrolizumab?

Answer from: Radiation Oncologist at Community Practice

In the KEYNOTE study which established pembro as SOC, they did report small but numerically increased (3.8 vs 1%) grade 3 skin toxicity in pembro arm vs placebo. That’s why the guidelines say it’s safe to administer IO with RT as the above protocol after amendment allowed concurrent IO p...

Comments

Radiation Oncologist at University of Texas Health Science Center San Antonio MD Anderson Mays Cancer Center
3.8 vs 1% are skin reactions during the neoadjuvan...

Answer from: Radiation Oncologist at Academic Institution

Yan et al., PMID 33137440

Answer from: Radiation Oncologist at Community Practice

Please select the option that best describes you:

Have you seen any increased dermatologic toxicity with whole breast or chest wall radiation if patients have received recent or concurrent pembrolizumab?

Related Questions